



**International Society for Cutaneous Lymphomas
Annual Scientific & Business Meeting
Ancillary Meeting at the 25th World Congress of Dermatology**

**Monday/July 3, 2023
9:00AM – 3:30PM Local Time
Suntec Singapore Convention & Exhibition Centre
Meeting Room: Summit 1 (Level 3)**

Meeting Chairpersons: Emmie Hodak and Larisa Geskin

Steering Committee:

- Emmie Hodak, Larisa Geskin, Julia Scarisbrick, Pietro Quaglino, Martine Bagot, Youn Kim (Dermatologists)
- Maxime Battistella, Alejandro Gru, Joan Guitart, Werner Kempf (Dermatopathologists)
- Steve Horwitz (Hematologist)

9:00AM – 9:15AM

Welcome and ISCL Annual Business Meeting
Emmie Hodak, ISCL President

***Standardization of Clinical and Pathologic Reports in Mycosis
Fungoides/Sézary Syndrome***

[Pre-Congress Workshop to the 5WCCL]

1. Introduction and Background

9:15AM – 9:25AM

Introduction
Emmie Hodak

2. Revisiting the Clinical Definitions of Patch, Plaque, Tumor

Moderators: Julia Scarisbrick & Pietro Quaglino

9:25AM – 9:35AM

Patch
Emmie Hodak

9:35AM – 9:55AM

Plaque
Pietro Quaglino

9:55AM – 10:05AM

Tumor
Julia Scarisbrick

10:05AM – 10:15AM

Discussion

3. Pathologic Reports

Moderators: Youn Kim, Christiane Querfeld, Larisa Geskin

Early Stage

10:15AM – 10:35AM Werner Kempf and Joan Guitart

Advanced Stage

10:35AM – 10:50AM **Tumor**
Alejandro Gru

10:55AM – 11:05AM **Erythroderma**
José Antonio Sanches

11:05AM – 11:20AM **Lymph Node**
Maxime Battistella and Larisa Geskin

11:20AM – 11:40AM **Folliculotropic Mycosis Fungoides**
Emmie Hodak, Maxime Battistella, Alejandro Gru

4. Is it the Right Time to Define T Classification Based on the Clinicopathological Correlation?

Moderators: Youn Kim, Emmie Hodak

11:40AM – 12:00PM **Discussion**
All Faculty

12:00PM – 1:00PM **Lunch and visiting exhibits**

5. Stage-Dependent Therapy in Mycosis Fungoides/Sézary Syndrome

Moderators: Lia Papadavid and Emmanuella Guenova

1:00PM – 1:25PM **Early stages**
Martine Bagot

1:25PM – 2:00PM **Advanced stages**
Rudi Stadler

6. Artificial Intelligence

Moderator: Aviv Barzilai

2:00PM – 2:15PM Larisa Geskin

2:15PM – 2:20PM **Discussion**

2:20PM – 2:30PM **Closing Remarks**

2:30PM – 3:30PM **Visit exhibits, free communication (posters)**

SCIENTIFIC ABSTRACT POSTERS

Basic research - etiology and pathogenesis

P-01 TNF- α inhibitors promote MF tumorigenesis

Ghazal Kheshaiboun 1,2, Ilanit Boyango¹, Emily Avitan-Hersh 1,2

1. Laboratory of skin cancer research, Department of Dermatology, The Clinical Research Institute at Rambam Health Care Campus, Haifa, Israel

2. Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa, Israel

Clinical and translational research

P-02 Where There's a WEKA, There's a Way: Development of a Scale for Early CTCL Diagnosis Using Machine Learning and Database Analysis

Emily R. Gordon BA, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY.

Megan H. Trager MD, Department of Dermatology, Columbia University Irving Medical Center, New York, NY.

Celine M. Schreidah BS, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY.

Oluwaseyi Adeuyan BS, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY.

Lauren M. Fahmy BS, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY.

Weijia Fan MS, Mailman School of Public Health, Columbia University, New York, NY.

Bradley D. Kwinta BA, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY.

Herbert S. Chase MD, Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY.

Larisa J. Geskin MD, Department of Dermatology, Columbia University Irving Medical Center, New York, NY.

P-03 Differences of Spatially Resolved Transcriptome Profile Between CD30-positive Large Cell Transformed Mycosis Fungoides and Primary Cutaneous Anaplastic Large Cell Lymphoma

Myoung Eun Choi, Mi Young Lee, Mi Woo Lee, Woo Jin Lee

Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

P-04 TRBC1 immunohistochemistry is a rapid and sensitive assay for the distinction of cutaneous T-cell lymphoma from inflammatory dermatitis

Sarah E. Nocco, MD, Mark D. Ewalt, MD, Andrea P. Moy, MD, Natasha E. Lewis, MD, Menglei Zhu, MD, PhD, Cecilia Lezcano, MD, Klaus Busam, MD, Melissa Pulitzer, MD (all at Memorial Sloan Kettering Cancer Center), USA

P-05 Study of PD1 and PDL1 expression in cutaneous T-cell lymphomas

Kovrigina Alla -The National Research Centre of Haematology, Russia
Sherstnev Andrey -The National Research Centre of Haematology, Russia
Mangasarova Yana -The National Research Centre of Haematology, Russia
Zvonkov Eugene -The National Research Centre of Haematology, Russia

P-06 Application of Natural Language Processing to Distinguish Signs and Symptoms of Cutaneous T-Cell Lymphoma in Electronic Health Record Patient Notes

Celine M. Schreidah [1], Adrian Garcia Hernandez [2], George Bingham Reynolds [2], Haoyang Shen [2], Zhaoyu Wu [2], Sung Jun Won [2], Lauren M. Fahmy [1], Emily R. Gordon [1], Benjamin L. May [3], Nicholas P. Tatonetti [2, 4, 5], Herbert S. Chase [2, 4], Itsik Pe'er [2, 6, 7], Larisa J. Geskin [3, 8]

[1] Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA

[2] The Data Science Institute at Columbia University, New York, NY, USA

[3] Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY, USA

[4] Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA

[5] Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, California, USA

[6] Department of Computer Science, Columbia University, New York, NY, USA

[7] Department of Systems Biology, Columbia University, New York, NY, USA

[8] Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA

Patient care in cutaneous lymphoma

P-07 Long-term outcomes and phenotypes associated with best responses to alemtuzumab in mycosis fungoides/Sézary Syndrome

Cecilia Larocca, M.D. (Harvard Medical School; Department of Dermatology, Brigham and Women's Hospital; Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center; Boston, MA, USA), Ai-Tram N. Bui, B.A. (Harvard Medical School; Boston, MA, USA), John T. O'Malley, M.D., Ph.D. (Harvard Medical School; Department of Dermatology, Brigham and Women's Hospital; Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center; Boston, MA, USA), Anita Giobbie-Hurder, M.S. (Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute; Boston, MA, USA), Cesar A. Virgen, M.D., Ph.D. (Harvard Medical School; Department of Dermatology, Brigham and Women's Hospital; Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center; Boston, MA, USA), Marianne Tawa, R.N., M.S.N., A.N.P. (Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center; Boston, MA, USA), Rachael A. Clark M.D., Ph.D. (Harvard Medical School; Department of Dermatology, Brigham and Women's Hospital; Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center; Boston, MA, USA), Eric Jacobsen, M.D. (Harvard Medical School; Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center; Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center; Boston, MA, USA), David C. Fisher, M.D. (Harvard Medical School;

Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center; Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center; Boston, MA, USA), Thomas S. Kupper, M.D. (Harvard Medical School; Department of Dermatology, Brigham and Women's Hospital; Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center; Boston, MA, USA), Nicole R. LeBoeuf, M.D., M.P.H. (Harvard Medical School; Department of Dermatology, Brigham and Women's Hospital; Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center; Boston, MA, USA).

P-08 Retreatment of CD30+ Lymphoproliferative Disorders with Brentuximab Vedotin

Auris Huen¹, Jessica Tran², Anna Zano², Stephen Gruschkus³, Madeleine Duvic¹
¹Department of Dermatology, The University of Texas MD Anderson Cancer Center
²Department of Dermatology, UTHealth McGovern Medical School
³Department of Biostatistics, The University of Texas MD Anderson Cancer Center

Primary Cutaneous Lymphoma

P-09 Cutaneous T-cell Lymphoma in a patient with Psoriasis under anti-TNF treatment

Marios Koumourtzis, Aristeidis Vaiopoulos, Kyriaki Lampadaki, Leonidas Marinos, Evangelia Papadavid
Dermatology Department, Attikon University Hospital, Greece

P-10 Two cases of primary cutaneous peripheral T-cell lymphoma, not otherwise specified

Makoto Sugaya¹, Yuta Norimatsu¹, Taro Akatsuka¹, Sohshi Morimura¹, Toshihisa Hamada¹, Yuichiro Hayashi², Takayuki Shiomi², Ryosuke Takenaka³, Kayoko Ohnishi³
¹Department of Dermatology, International University of Health and Welfare, Chiba, Japan
²Department of Pathology, International University of Health and Welfare, Chiba, Japan
³Department of Radiology, International University of Health and Welfare, Chiba, Japan

P-11 pcALCL in two pediatric patients: report and literature review

Vashurin Ilan^{1,2}, Greenberger Shoshana^{1,2}, Barzilai Aviv^{1,2}
¹Department of Dermatology, Sheba Medical Center, Ramat-Gan, Israel
²Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel

P-12 Clonal Evolution in Mycosis Fungoides and Sézary Syndrome by Next-Generation Sequencing

Jasmine Zain², Liliana Crisan¹, Michelle Afkhami¹, Raju Pillai¹, Huiyan Ma¹, Steven Rosen^{2,3}, Christiane Querfeld^{1,2,3}
¹Department of Pathology, ²Department of Hematology and Stem Cell Transplantation, ³Beckman Research Institute, City of Hope, Duarte, CA, USA